1150617-54-1

Basic information

• Product Name: 6-Bromo-1H-pyrazolo[4,3-b]pyridine
• Synonyms: 6-Bromo-1H-pyrazolo[4,3-b]pyridine;6-Bromo-1H-pyrazolo[4,3-b...;1H-Pyrazolo[4,3-b]pyridine, 6-broMo-;6-broMo-1H-pyrazolo[4;3-Cya-4-nitro-1H-indazole
• CAS NO: 1150617-54-1
• Molecular Formula: C₆H₄BrN₃
• Molecular Weight: 198.02006
• Product Categories: Heterocycle-Pyridine series
• Mol File: 1150617-54-1.mol

Chemical Properties

• Boiling Point: 328.998 °C at 760 mmHg
• Flash Point: 152.773 °C
• Appearance: /
• Density: 1.894
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 9.72±0.40(Predicted)
• CAS DataBase Reference: 6-Bromo-1H-pyrazolo[4,3-b]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-1H-pyrazolo[4,3-b]pyridine(1150617-54-1)
• EPA Substance Registry System: 6-Bromo-1H-pyrazolo[4,3-b]pyridine(1150617-54-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 1150617-54-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
6-Bromo-1H-pyrazolo[4,3-b]pyridine is utilized as a key building block in the synthesis of pharmaceuticals. Its unique structure allows for the creation of diverse drug candidates with potential therapeutic applications. 6-Bromo-1H-pyrazolo[4,3-b]pyridine's ability to be integrated into various molecular frameworks makes it a valuable asset in the development of novel medications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 6-Bromo-1H-pyrazolo[4,3-b]pyridine is employed as a reagent to introduce the pyrazolo[4,3-b]pyridine moiety into different molecules. This incorporation can enhance the biological activity and pharmacological properties of the resulting compounds, contributing to the advancement of drug discovery and design.
Used in Organic Chemical Reactions:
6-Bromo-1H-pyrazolo[4,3-b]pyridine also serves as a reagent in organic chemical reactions, where it can be used to modify or functionalize other organic molecules. Its presence in these reactions can lead to the formation of new compounds with improved or novel properties, expanding the scope of organic synthesis.
Used in Drug Development:
Due to its potential biological activities, 6-Bromo-1H-pyrazolo[4,3-b]pyridine is studied for its potential use in the development of new drugs. Its incorporation into drug candidates can lead to the discovery of compounds with therapeutic benefits, making it an important component in the pharmaceutical industry's pursuit of innovative treatments.

Upstream product

• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 

Downstream Products

• 1256807-59-6 1H-pyrazolo[4,3-b] pyridine-6-carboxylic acid 
• 1383735-30-5 ethyl 1H-pyrazolo[4,3-b]pyridine-6-carboxylate 
• 1614234-22-8 6-(3,5-dimethoxyphenyl)-3-iodo-1H-pyrazolo[4,3-b]pyridine 
• 1614234-23-9 6-(3,5-dimethoxyphenyl)-3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-b]pyridine 
• 1614234-24-0 6-(2,6-dichloro-3,5-dimethoxyphenyl)-3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-b]pyridine 
• 1614234-25-1 6-(2,6-dichloro-3,5-dimethoxyphenyl)-3-(1H-pyrazol-4-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[4,3-b]pyridine 
• 1150617-56-3 6-bromo-1-methyl-1H-pyrazolo[4,3-b]pyridine 

Relevant articles and documents

HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions in need of inhibition of heparan sulfate biosynthesis.

PYRAZOLOPIPERIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.

N1/N2-Lactam Acetyl-CoA carboxylase inhibitors

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal

N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions there-of; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl- CoA carboxylase enzyme(s) in an animal

N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl- CoA carboxylase enzyme(s) in an animal.